| AGS-003 improved OS in unfavorable-risk metastatic renal cell carcinoma - HemOncToday |
|
|
HemOncToday Adding AGS-003 to sunitinib extended survival for patients with metastatic renal cell carcinoma compared with sunitinib monotherapy, according to results of a phase 2 study. Previous study results showed that AGS-003, a personalized dendritic-cell |